$ZURA

Zura Bio Ltd

Zura Bio is a clinical-stage biotechnology company developing antibody-based medicines for patients with autoimmune and inflammatory diseases. Its three in-licensed product candidates are tibulizumab, a bispecific antibody targeting IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7Rα; and torudokimab, a monoclonal antibody targeting IL-33. Zura Bio is conducting two global Phase 2 trials of tibulizumab in adults with hidradenitis suppurativa and diffuse cutaneous systemic sclerosis. Crebankitug and torudokimab were evaluated in earlier clinical trials, and the company is assessing potential development strategies for them. Zura Bio has no products approved for commercial sale. It licenses rights to its product candidates and uses contract manufacturers to produce drug substance and finished drug products. Its business is headquartered in La Jolla, California.

AlphAI earnings readthird quarter 2026 · OCT 27Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate UpdatesVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $ZURA in the last 7 days.

No SEC Form 4 filings for $ZURA in the last 30 days.

See all $ZURA insider activity →
High

Biotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13%

PepGen (PEPG) surged 114% after positive Phase 2 data for its muscular dystrophy treatment. Zura Bio (ZURA) rose 15% despite discontinuing a clinical program. NeOnc (NTHI) gained 13% following CEO share purchases. Senseonics (SENS) advanced 12% after raising its revenue outlook on strong Q3 growth.

ZURA sentiment & insider activity

Recent ZURA coverage spans financial news, earnings and market movers.

What's driving ZURA

AlphAI scores every news story that mentions ZURA with an AI model for sentiment and relevance, and aggregates insider trades from Zura Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZURA

Score
$ZURAHighAI 8/10

Zura Bio Ends HS Development After Phase 2 TibuSHIELD Misses Endpoints

Zura Bio (ZURA) halted hidradenitis suppurativa (HS) development after its Phase 2 TibuSHIELD study missed primary and key secondary endpoints. The study showed 56.0% and 58.1% reductions in abscess and nodule counts for tibulizumab doses, versus 52.5% for placebo. The company will continue other studies and expects $187.7 million in cash to fund operations through at least 2028.

$ZURAHighAI 8/10Clinical / regulatory· topline data

Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa November 9, 2026 7:00 AM

Zura Bio Ltd (ZURA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa November 9, 2026 7:00 AM · Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at

Guggenheim reiterates Zura Bio stock rating on HS market potential

Guggenheim reiterated a Buy rating and $20 price target for Zura Bio (ZURA), citing potential in its drug Tibulizumab for hidradenitis suppurativa. The stock has gained 17.9% in a week. Guggenheim projects a $14B HS market by 2035, with Tibulizumab potentially capturing 10% of it. Zura Bio reported Q2 2026 earnings and plans to test Tibulizumab for polymyalgia rheumatica. Guggenheim raised its price target from $15 to $20. Wedbush also recommended buying shares ahead of trial results.

Related tickers